Halozyme Appoints David Ramsay as Interim Chief Financial Officer

Core Viewpoint - Halozyme Therapeutics has appointed David Ramsay as Interim Chief Financial Officer, effective March 23, 2026, while the company searches for a permanent CFO [1] Group 1: Appointment Details - David Ramsay has over 30 years of strategic financial leadership experience in biotechnology and life sciences [1] - He previously served as Halozyme's CFO from 2003 to 2009 and again from 2013 to 2015, during which the company grew into a billion-dollar public biopharmaceutical entity [1] - Ramsay's prior experience includes serving as Senior Vice President and CFO of Bonti, Inc. until its acquisition by Allergan in October 2018 [1] Group 2: Executive Search - Halozyme is actively searching for a permanent CFO and has engaged a leading executive search firm to identify suitable candidates [1] - The search is focused on candidates with expertise in capital markets and strategic planning [1] Group 3: Company Overview - Halozyme is a biopharmaceutical company known for its ENHANZE® drug delivery technology, which facilitates subcutaneous delivery of drugs, improving patient convenience [1] - The technology has impacted over one million patients through ten commercialized products across more than 100 global markets [1] - Halozyme has expanded its technology portfolio with Hypercon™ and Surf Bio's hyperconcentration technology, enhancing the delivery of biologics [1]